Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 9, 2020
Daily News
November 9, 2020
- Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
- Kyorin Jettisons Gene Therapy Ad-SGE-REIC after Bleak PII Results
November 9, 2020
- Swiftly Disclose PAFSC Minutes for COVID-19 Vaccines: Opposition Parties
November 9, 2020
- JPMA Sorts Out Challenges for Remote Clinical Trial to Promote Its Introduction in Japan
November 9, 2020
- Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
- MHLW to Appropriately Handle FY2021 Off-Year Re-Pricing Debate: Minister
November 9, 2020
- Xtandi Approved in China for Non-Metastatic CRPC
November 9, 2020
- Keytruda Top Selling Drug for 3 Months on End: Encise October Data
November 9, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…